Phagenesis

Phagenesis Ltd is a private medical technology company focused on innovative treatments for neurogenic dysphagia, a swallowing disorder linked to neurological impairment. Founded in 2007 by Dr. Conor Mulrooney and Professor Shaheen Hamdy from the University of Manchester, the company has developed the Phagenyx® Neurostimulation System. This device uses pharyngeal electrical stimulation to restore swallowing function by targeting the neurological control of swallowing. The Phagenyx® system features a naso-gastric catheter with bipolar ring electrodes that deliver electrical stimulation to the pharyngeal mucosa. This stimulation promotes neuroplasticity, enhancing sensory feedback essential for safe swallowing. Clinical trials have shown that the device significantly improves swallowing function, accelerates recovery, and reduces hospital stays. It is currently in use across the UK and Europe, benefiting many patients with swallowing difficulties and is recommended in clinical guidelines for stroke care. Phagenesis primarily serves healthcare providers, including hospitals and rehabilitation centers, treating patients with neurogenic dysphagia. The company is working to expand its reach, particularly in the United States, with support from life sciences investors.

• Employees 57
• Founded 2007
• Annual Revenue $4300000
• Total Funding $72891330